{"Clinical Trial ID": "NCT00871858", "Intervention": ["INTERVENTION 1:", "- Arm A (ANA)", "Patients receive oral anastrozole as 1 mg film-coated tablets once daily for 6 months.", "Anastrozole: oral", "INTERVENTION 2:", "- Arm B (FULV)", "Patients receive intramuscularly (250 mg/5 ml solution) on days 1, 14 and 28 and once a month up to 6 months.", "Fulvestrant: administered intramuscularly"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Invasive breast cancer, confirmed histologically, meets 1 of the following criteria:", "(patients under 65 years of age)", "SBR grade I-III disease (patients > 65 years)", "T2 (2-5 cm), T3, or T4B, and N0-1 disease", "No metastatic disease", "The breast injury is not suitable for breast conservation resection.", "No inflammatory breast cancer", "No previous breast cancer", "- Hormonal receptor status:", "- Positive estrogen and/or progesterone receptor", "CHARACTERISTICS OF PATIENTS:", "Postmenopausal menopausal", "No other cancers in the last 5 years except skin carcinoma or carcinoma properly treated in situ of the cervix", "No contraindications for anti-hormonal treatment", "There are no psychological, family, social or geographical reasons that would prevent follow-up", "THERAPE PRIOR CONCURENT:", "At least 8 days since previous hormone replacement therapy", "No concomitant treatment for vitamin K"], "Results": ["Performance measures:", "Objective response rate (ORR) determined by clinical palpation", "The objective response rate is defined as the partial or complete response rate of participants according to RECIST V1.0.", "The complete response is defined as the disappearance of all the target lesions and the partial response is defined as a decrease of at least 30% in the sum of the longest diameters (LDS) of the target lesions, taking as reference the initial LDS (RECIST V1.0.).", "Time limit: 6 months", "Results 1:", "Title of arm/group: Arm A (ANA)", "Description arm/group: Patients receive oral anastrozole as 1 mg film-coated tablets once daily for 6 months.", "Anastrozole: oral", "Total number of participants analysed: 56", "Type of measurement: Number", "Unit of measure: percentage of participants 58.9 (45.0 to 71.9)", "Results 2:", "Title of arm/group: Arm B (FULV)", "- Arm/group description: Patients receive intramuscular (250 mg/5 ml solution) on days 1, 14 and 28 and once a month up to 6 months.", "Fulvestrant: administered intramuscularly", "Total number of participants analysed: 52", "Type of measurement: Number", "Unit of measure: percentage of participants 53.8 (39.5 to 67.8)"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/60 (3.33%)", "- bronchial infection 0/60 (0.00 %)", "Ankle fracture 1/60 (1.67%)", "- Clear cell kidney cancer 0/60 (0.00 %)", "Programmed peritoneal dialysis 1/60 (1.67%)", "Atrophy of endometrium 0/60 (0.00 %)", "Adverse Events 2:", "Total: 3/58 (5.17 per cent)", "- bronchial infection 1/58 (1.72%)", "- Ankle fracture 0/58 (0.00 %)", "- Clear cell kidney cancer 1/58 (1.72%)", "Programmed peritoneal dialysis 0/58 (0.00 %)", "Atrophy of endometrium 1/58 (1.72%)"]}